braftovi
pierre fabre medicament - encorafenib - melanoma; colorectal neoplasms - antineoplastiski līdzekļi - encorafenib is indicated:in combination with binimetinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutationin combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (crc) with a braf v600e mutation, who have received prior systemic therapy.
everolimus krka 10 mg tabletes
krka, d.d., novo mesto, slovenia - everolims - tablete - 10 mg
everolimus krka 5 mg tabletes
krka, d.d., novo mesto, slovenia - everolims - tablete - 5 mg
everolimus krka 2,5 mg tabletes
krka, d.d., novo mesto, slovenia - everolims - tablete - 2,5 mg
everolimus sandoz 2,5 mg tabletes
sandoz d.d., slovenia - everolims - tablete - 2,5 mg
everolimus sandoz 5 mg tabletes
sandoz d.d., slovenia - everolims - tablete - 5 mg
everolimus sandoz 10 mg tabletes
sandoz d.d., slovenia - everolims - tablete - 10 mg
sunitinib sandoz 37,5 mg cietās kapsulas
sandoz d.d., slovenia - sunitinibs - kapsula, cietā - 37,5 mg
sunitinib sandoz 12,5 mg cietās kapsulas
sandoz d.d., slovenia - sunitinibs - kapsula, cietā - 12,5 mg
sunitinib mylan 12,5 mg cietās kapsulas
mylan ireland limited, ireland - sunitinibs - kapsula, cietā - 12,5 mg